title: Effects of nebivolol on artery hypertension--multicentre study Bosnia and Herzegovina.
abstract: Hypertension is a major risk factor for cardiovascular diseases; drugs that reduce blood pressure and simultaneously improve or reverse endothelian dysfunction, as nebivolol, may be advantageous in terms of cardiovascular protection. The objective of this study is to show the anti-hypertensive efficacy and safety of nebivolol (5 mg once a day) given to patients with arterial hypertension for 3 months. It should also provide information about drug's influence on laboratory tests--fasting blood glucose and serum cholesterol, triglyceride and creatinine concentrations. Six centers--Tuzla, Sarajevo, Mostar, Bihac, Zenica and Banja Luka participated in this prospective study with follow-up period of 3 months that included 3 visits. The study group consisted of 328 hypertensic patients. Results showed a significant decrease in both systolic and diastolic blood pressure and heart rate at the end of the study. Fasting blood glucose level and serum cholesterol, triglyceride and creatinine changed significantly during the study, with lower levels of all the tests. Nebivolol seems to be free from some of the problems that generally accompany not only the classical beta- blockers but sometimes also newer classes of antihypertensive drugs. With its high anti-hypertensive efficiency and safety, and presence of statically significant difference in laboratory tests and beneficial effects, absence of adverse interaction with glucose and lipid metabolism, patients treated with Nebivolol may show an optimal adherence to therapy.
authors.affiliation: Department of Cardiology, University Clinics Center Tuzla, Trnovac bb, 75000 Tuzla, Bosnia and Herzegovina.
authors.forename: Zumreta
authors.initials: Z
authors.lastname: Kusljugić
authors.forename: Katarina
authors.initials: K
authors.lastname: Divković
authors.forename: Fahir
authors.initials: F
authors.lastname: Baraković
authors.forename: Elnur
authors.initials: E
authors.lastname: Smajić
authors.forename: Amila
authors.initials: A
authors.lastname: Arslanagić
authors.forename: Mustafa
authors.initials: M
authors.lastname: Hadziomerović
authors.forename: Emir
authors.initials: E
authors.lastname: Fazlibegović
authors.forename: Zlatko
authors.initials: Z
authors.lastname: Midzić
authors.forename: Enes
authors.initials: E
authors.lastname: Abdović
authors.forename: Milenko
authors.initials: M
authors.lastname: Krneta
authors.forename: Radenko
authors.initials: R
authors.lastname: Celik
authors.forename: Hajro
authors.initials: H
authors.lastname: Basić
authors.forename: Bajro
authors.initials: B
authors.lastname: Avdić
authors.forename: Adnan
authors.initials: A
authors.lastname: Delić
authors.forename: Amra
authors.initials: A
authors.lastname: Macić-Dzanković
authors.forename: Nedzad
authors.initials: N
authors.lastname: Keco
authors.forename: Hajra
authors.initials: H
authors.lastname: Boskailo
mesh_terms: D000704:Analysis of Variance; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001578:Benzopyrans / Q000627:therapeutic use*; D017522:Bosnia and Herzegovina; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000068577:Nebivolol; D011446:Prospective Studies; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D001578:Benzopyrans; D004983:Ethanolamines; D000068577:Nebivolol